Sutro Biopharma

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics.

[Sutro Biopharma @SutroBio]

We’re excited to share that our Chief Scientific Officer, Hans-Peter Gerber, Ph.D., will be participating in a panel discussion at @Biocentury 3rd Grand Rounds U.S., taking place June 3–5, 2026 in Seattle, Washington.
#SutroBio #BioCentury $STRO

[Sutro Biopharma @SutroBio]

We’re excited to join the life science community at the @Jefferies Global Healthcare Conference in NYC. Sutro's presentation, which takes place tomorrow, June 4th at 9:20 a.m. ET, and available via webcast, here: https://t.co/ysVTJL0pEy
#JefferiesHealthcare #SutroBio $STRO

[Sutro Biopharma @SutroBio]

Don’t miss it! Today at 12:30 p.m. ET, members of the Sutro management team will participate in the virtual @TDSecurities Cowen's 7th Annual Oncology Innovation Summit. Join the webcast here: https://t.co/FX25G6I8jn
#SutroBio $STRO

[Sutro Biopharma @SutroBio]

Jane Chung, CEO sat down with @BiotechTV to walk through Sutro's growing ADC pipeline — single- and dual-payload programs, key partnerships, and the science behind our approach to cancer therapeutics.
Thanks for the feature, BiotechTV! Watch the full video to learn more.
$STRO

[BiotechTV @BiotechTV]

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: @SutroBio is developing next generation antibody-drug conjugates, including dual payload ADCs. CEO Jane Chung walks us through their programs. $STRO

Full video: https://t.co/1d32JB97ZA

[Sutro Biopharma @SutroBio]

Pleased to contribute to @BioCentury Inc.’s latest article on ADC innovation, featuring insights from our CSO Hans-Peter Gerber on next-gen linker technologies: https://t.co/odkRM20j3h #BioCentury #SutroBio $STRO

[Sutro Biopharma @SutroBio]

Today, we reported our Q1 2026 financial results and business highlights. The full press release can be found here: https://t.co/pcvF7QKywz
#SutroBio $STRO

[Sutro Biopharma @SutroBio]

We’re pleased to share updates from Sutro Biopharma at the American Association for Cancer Research (@AACR) Annual Meeting 2026.
Thank you to the AACR community for the thoughtful discussions throughout the meeting. #AACR26 #SutroBio $STRO

[Sutro Biopharma @SutroBio]

We’re pleased to present promising preclinical data across our ADC pipeline at the @AACR Annual Meeting 2026. For more info, https://t.co/chVQyYwBxu
$STRO #SutroBio #AACR26

[Sutro Biopharma @SutroBio]

We’re pleased to be presenting at the upcoming @AACR Annual Meeting 2026 in San Diego next month, including an oral presentation and 5 posters. More info here: https://t.co/MuHBj4SKIl
#AACR26 #SutroBio $STRO

[Sutro Biopharma @SutroBio]

Today, we reported our Q4 YE 2025 financial results and business highlights. The full press release can be found here: https://t.co/MuHBj4SKIl
#SutroBio $STRO

[Sutro Biopharma @SutroBio]

Don't miss it! Today, the STRO management team will present at the @CitizensBank Life Sciences Conference. Tune in via webcast here: https://t.co/0l3IcNqldi
$STRO #SutroBio

[Sutro Biopharma @SutroBio]

Jane Chung, Chief Executive Officer, will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference today, March 4th at 1:50PM EST. Click the link to register and join the live webcast: https://t.co/cCVMLqot8L #SutroBio $STRO

[Sutro Biopharma @SutroBio]

We look forward to attending the upcoming investor conferences. For more info: https://t.co/xarlueIg3Q
@TDBank_US @LeerinkPartners @CitizensBank @Barclays $STRO #SutroBio

[Sutro Biopharma @SutroBio]

We’re participating in the 16th Annual @World_ADC London Summit. Sutro CSO Hans-Peter Gerber will speak in three sessions on the evolving ADC landscape. More: https://t.co/v4XhZeF6mD

[Sutro Biopharma @SutroBio]

This week, Sutro announced a $110M financing, extending the company's cash runway and supporting continued advancement of our ADC pipeline and upcoming milestones. More details here: https://t.co/BQ9zzwMuHk #SutroBio #CancerResearch $STRO

[Sutro Biopharma @SutroBio]

Join us today as Jane Chung, CEO of Sutro Biopharma, presents at the J.P. Morgan Healthcare Conference. We’ll be discussing our advancements in ADC technology and upcoming milestones. Tune in at 11:15AM PST / 2:15PM EST. https://t.co/q2GZHEDTcf
#JPM2026

[Sutro Biopharma @SutroBio]

We’re pleased to announce that our CEO, Jane Chung, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, Jan 15th at 11:15AM PST / 2:15PM EST. We look forward to sharing the latest on our novel ADC platform and our vision for the future of oncology. For more info: https://t.co/WLQGn5dcCS

#JPM2026

[Sutro Biopharma @SutroBio]

We’re excited to welcome Kari Leetch to Sutro as our new SVP, Head of People & Culture. We’re thrilled to have her leadership and expertise on the team.

[Sutro Biopharma @SutroBio]

We’re excited to share that the first cohort of patients has been dosed in our Ph 1 trial of STRO-004, our next-gen TF-targeting exatecan ADC—an important step forward in advancing next-generation ADCs for patients. For more info: https://t.co/32m4szZwOU
#SutroBio #CancerResearch $STRO

[Sutro Biopharma @SutroBio]

Jane Chung, Chief Executive Officer, will participate in the @Piper_Sandler 37th Annual Healthcare Conference on Dec 3rd at 3:30PM EST. For more information, https://t.co/0Xf9ACJjMX
#SutroBio #PSCHealthcare2025 #CancerResearch $STRO